Design, synthesis and biological evaluation of novel 2-(4-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors

Xing-Rong Wang,Shuai Wang,Wen-Bo Li,Kai-Yan Xu,Xue-Peng Qiao,Xue-Li Jing,Zi-Xiao Wang,Chang-jiang Yang,Shi-Wu Chen
DOI: https://doi.org/10.1016/j.ejmech.2021.113192
IF: 7.088
2021-01-01
European Journal of Medicinal Chemistry
Abstract:Vascular endothelial growth factor-2 (VEGFR-2) plays a pivotal role in tumor angiogenesis. Herein, a library of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives were designed and synthesized as VEGFR-2 inhibitors based on scaffold hopping strategy. These compounds exhibited the excellent inhibitory in both VEGFR-2 and tumor cells proliferation. Especially, compound W13 possessed potent VEGFR-2 inhibition with IC50 = 1.6 nM and anti-proliferation against HGC-27 tumor cells with IC50 = 0.36 +/- 0.11 mu M, as well as less toxicity against normal GES-1 cells with IC50 = 187.46 +/- 10.13 mu M. Moreover, W13 obviously inhibited colony formation, migration and invasion of HGC-27 cells by adjusting the expression of MMP-9 and E-cadherin, and induced HGC-27 cells apoptosis by increasing ROS production and regulating the expression of apoptotic proteins. Furthermore, W13 blocked the PI3K-Akt-mTOR signaling pathway in HGC-27 cells. In addition, anti-angiogenesis of W13 was proved by inhibiting tube formation and the expression of p-VEGFR-2 in HUVEC cells. All the results demonstrated that W13 could be developing as a promising anticancer agent for gastric cancer therapy. (C) 2021 Elsevier Masson SAS. All rights reserved.
What problem does this paper attempt to address?